# Avilar Therapeutics

> Avilar Therapeutics is a Waltham, Massachusetts biopharmaceutical company pioneering the degradation of extracellular and membrane-bound proteins. Its ATAC (ASGPR Targeting Chimera) platform uses bifunctional small molecules that grab a disease-causing protein floating in circulation and shuttle it into the liver's endolysosome to be destroyed, extending the reach of targeted protein degradation beyond the inside of the cell. Launched in 2021 with backing from RA Capital, Avilar is applying the platform to autoimmune disease, preeclampsia, and other conditions driven by proteins that conventional drugs struggle to address.

- **Founded:** 2021
- **Headquarters:** Waltham, Massachusetts, United States
- **Founders:** Milind Deshpande (Co-Founder & Board Chairman; RA Capital venture partner), Daniel Grau (Founding CEO & President (early stage))
- **Team size:** ~24 employees
- **Products:** ATAC Platform (ASGPR Targeting Chimeras), mTAC Platform (M6PR Targeting Chimeras), Preeclampsia / sFlt1 Program, IgG / Autoimmune Program
- **Notable:** Launched in 2021 with a $60M seed financing from RA Capital to pioneer extracellular protein degradation., Expanded financing to $75M in February 2023 with Sanofi Ventures, Astellas Venture Management and MEC joining., Demonstrated ~85% reduction in IgG from a single subcutaneous ATAC dose in a non-human primate study.

## Products & services

- **ATAC Platform (ASGPR Targeting Chimeras)** — Bifunctional small molecules that pair a proprietary high-affinity ligand for the liver's asialoglycoprotein receptor (ASGPR) with a binder for a disease-causing extracellular protein, shuttling that protein from circulation into the endolysosome for degradation.
- **mTAC Platform (M6PR Targeting Chimeras)** — An extension of the degrader concept using ligands to the mannose-6-phosphate receptor (M6PR) to reach additional extracellular and membrane-associated targets.
- **Preeclampsia / sFlt1 Program** — An ATAC designed to selectively bind and clear soluble fms-like tyrosine kinase-1 (sFlt1), a central driver of preeclampsia, with the goal of stopping or reversing disease progression and prolonging pregnancy.
- **IgG / Autoimmune Program** — A monovalent ATAC that reduced IgG by roughly 85% in a repeat-dose non-human primate study, targeting pathogenic autoantibodies implicated in multiple autoimmune diseases.

## Achievements

- Launched in 2021 with a $60M seed financing from RA Capital to pioneer extracellular protein degradation.
- Expanded financing to $75M in February 2023 with Sanofi Ventures, Astellas Venture Management and MEC joining.
- Demonstrated ~85% reduction in IgG from a single subcutaneous ATAC dose in a non-human primate study.
- Awarded U.S. Patent 11,819,551 (issued Nov 21, 2023) covering its first wave of ATAC extracellular protein degraders.
- Built a modular discovery platform with proprietary high-affinity small-molecule ASGPR ligands.

## Latest updates

- **2023-11** — Received U.S. Patent 11,819,551 providing broad protection for its ATAC extracellular protein degraders.
- **2023-02** — Increased total financing to $75M with new investors Sanofi Ventures, Astellas Venture Management and Medical Excellence Capital.
- **2021-11** — Launched publicly with $60M seed financing from RA Capital Management.

## Links

- Website: https://avilar-tx.com
- LinkedIn: https://www.linkedin.com/company/avilar-therapeutics
- Twitter/X: https://twitter.com/Avilar_Tx

---

Profile page: https://yespress.io/avilar-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-07